- Total income
- ₹7,616 Cr
- Profit
- ₹839 Cr
About Jubilant Pharmova
Jubilant Pharmova is a publicly listed company based in Amroha (India) founded in 2020. CDMO focused on manufacturing of solid, semi solid, liquid, and injectible drug formulations. The company has 165 employees. Its chief executive, as recorded, is Jaidev Rajpal. Its Indian entity Jubilant Pharmova Limited reported revenue of ₹8,346 Cr. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Similar companies include Akums, Jubilant Life Sciences and Nectar Lifesciences; 2 of its 3 listed similar companies have raised funding.
Company details
Jubilant Pharmova was founded in 2020 in Amroha, India, within the pharmaceutical sector. Operations are centered on contract development and manufacturing services for solid, semi-solid, liquid, and injectable drug formulations. The company is headquartered in India, with its domain registered as jubilantpharmova.com. Leadership is provided by CEO Jaidev Rajpal, overseeing production activities for pharmaceutical clients.
Jubilant Pharmova is ranked #334 on the Fortune India 500 (2025).
Recognitions & Rankings of Jubilant Pharmova
- Valuation
- ₹18,570 Cr
- Market Cap₹14,867 Cr
JUBLPHARMA · NSE
- Share Price₹935.05
+0.19% today
- Revenue₹8,280 Cr
FY 2025-26 · +14.5% YoY
- EBITDA₹1,200 Cr
Margin 14.5%
- Net Profit₹436 Cr
FY 2025-26 · +9.1% YoY
- P/E (TTM)50.4x
P/B 2.1x
- ROE6.0%
ROCE 6.9%
- Debt / Equity0.48
Interest cover 27.9x
- Employee Count165
Associated legal entities of Jubilant Pharmova
Jubilant Pharmova is associated with 2 registered companies on The Company Check; the primary company is Jubilant Pharmova Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Jubilant Pharmova Limited Listed CIN L24116UP1978PLC004624 | Active | 21 Jun 1978 | ₹8,346 Cr | 1,055 | 12 | View details | |
| Vanthys Pharmaceutical Development Private Limited CIN U73100UP2009PTC037333 | Dissolved (Liquidated) | 11 May 2009 | Noida, Uttar Pradesh | ₹0.3 Cr | 6 | View details |
Apps and channels of Jubilant Pharmova
its YouTube channel Jubilant Pharmova has 285 subscribers and 20 videos.
Videos from Jubilant Pharmova
The most watched videos on Jubilant Pharmova's YouTube channel, Jubilant Pharmova (285 subscribers). Click a video to play it here.
More on Jubilant Pharmova.
Board of directors of Jubilant Pharmova Limited (Jubilant Pharmova)
Jubilant Pharmova Limited is the primary company behind Jubilant Pharmova. The boards of the 2 registered companies of Jubilant Pharmova currently have 14 directors; the longest-serving is Shyam Sunder Bhartia, appointed in 1978. 52 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Shyam Sunder Bhartia DIN 00010484 | Director | 21 Jun 1978 | 48 yrs 5 mo | Jubilant Pharmova Limited |
| Hari Shanker Bhartia DIN 00010499 | Director | 01 Nov 1983 | 43 yrs | Jubilant Pharmova Limited |
| Priyavrat Bhartia DIN 00020603 | Managing Director | 23 May 2017 | 9 yrs 5 mo | Jubilant Pharmova Limited |
| Arjun Shanker Bhartia DIN 03019690 | Managing Director | 23 May 2017 | 9 yrs 5 mo | Jubilant Pharmova Limited |
| Vivek Mehra DIN 00101328 | Director | 23 May 2017 | 9 yrs 5 mo | Jubilant Pharmova Limited |
| Sushil Kumar Roongta DIN 00309302 | Director | 23 May 2017 | 9 yrs 5 mo | Jubilant Pharmova Limited |
| Shwetank Tiwari DIN 02413671 | Company Secretary | 16 Jan 2018 | 8 yrs 10 mo | Vanthys Pharmaceutical Development Private Limited |
| Benny Thomas DIN 07241561 | Director | 28 Mar 2018 | 8 yrs 7 mo | Vanthys Pharmaceutical Development Private Limited |
| Shyamsundar Bang DIN 00011327 | Director | 28 Mar 2018 | 8 yrs 7 mo | Vanthys Pharmaceutical Development Private Limited |
| Arun Seth DIN 00204434 | Director | 22 Oct 2018 | 8 yrs 1 mo | Jubilant Pharmova Limited |
| Saravanakumar Dhakshinamoorthy DIN 08448999 | Additional Director | 15 May 2019 | 7 yrs 6 mo | Vanthys Pharmaceutical Development Private Limited |
| Shirish Gundopant Belapure DIN 02219458 | Director | 07 Mar 2023 | 3 yrs 8 mo | Jubilant Pharmova Limited |
| Shivpriya Nanda DIN 01313356 | Director | 01 Apr 2024 | 2 yrs 7 mo | Jubilant Pharmova Limited |
| Harsh Mahajan DIN 00824227 | Director | 01 Apr 2024 | 2 yrs 7 mo | Jubilant Pharmova Limited |
People of Jubilant Pharmova
91 people are tracked at Jubilant Pharmova (47 in leadership, 44 in team); the tracked headcount is 165.
| Name | Role | Group |
|---|---|---|
Jaidev Rajpal | CEO | Leadership |
Apratim Bose | Head Digital - Pharmova & Site IT Head - Radiopharma | Leadership |
Jagdish Mahajan | Senior Director - International Marketing (non Us) | Leadership |
Ashok Kumar Gupta | Deputy General Manager Supply Chain | Leadership |
Lt Col Kamaljeet Singh Pabla | Senior Director And Group Head - Adminstration, Corporate Services,security & Vigilance | Leadership |
Shailendra Chaudhari | Head- Manufacturing & Operational Excellence And Technical Services | Leadership |
Satyanarayana Potlacheruvu | Associate Director - CSV | Leadership |
| Managing Director | Leadership | |
| Joint Managing Director | Leadership | |
Chris Preti | Ceo - Cdmo | Leadership |
Ashish Sinha | Vice President & SBU Head - Animal And Human Nutrition & Health Solutions | Leadership |
Brian Enright | Senior Vice President, Quality | Leadership |
Gayatri Taragi | Global Head - Rewards | Leadership |
Piyush Agarwal | Vp, Finance | HEAD - Risk, Treasury & Assurance | Leadership |
Jasdeep Singh Sood | Sr. Vice President & Head : Emerging Markets (global Formulation Business Excluding Usa) | Leadership |
Anupam Malhotra | Head (general Manager)- Technology Transfer | Leadership |
Sukhpal Singh | GU Head (associate Vice President) | Leadership |
Vikas Gandhi | Associate Director ( Sales Head Latin America,middle East, Africa And India) | Leadership |
Manish Papnai | Associate Director Compensation & Benefits | Leadership |
Ankush Raman Sharma | Director | Leadership |
71 more people are available in the full profile.
Complete people profiles for Jubilant Pharmova
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Jubilant Pharmova
Jubilant Pharmova is a publicly listed company on the NSE with ticker symbol JUBLPHARMA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Jun 2003
- Listed onNSE: JUBLPHARMA
- Listed entityJubilant Pharmova Limited
- Exchange sectorHealth technology
- ISININE700A01033
- Share price₹938.90 (-0.38% on the day) · 2026-10-14
- Market capitalisation₹15,019 Cr
- Price to earnings42.3
- EPS (diluted, trailing year)₹22.18
- Dividend yield0.53%
- Volume (last session)391,864
Financials of Jubilant Pharmova
Exchange-reported figures of Jubilant Pharmova Limited, the listed company behind Jubilant Pharmova (NSE: JUBLPHARMA).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 8,280 | 7,234 | 6,703 | 6,282 | 6,130 | 6,099 | 5,976 |
| Revenue growth | +14.5% | +7.9% | +6.7% | +2.5% | +0.5% | +2.1% | - |
| EBITDA | 1,200 | 1,173 | 732 | 719 | 1,146 | 1,375 | 1,515 |
| EBITDA margin | +14.5% | +16.2% | +10.9% | +11.5% | +18.7% | +22.6% | +25.4% |
| Profit before tax | 614 | 981 | 170 | 27.80 | 630 | 1,133 | 1,233 |
| Net profit | 436 | 400 | 45.30 | (389) | 416 | 856 | 922 |
| Net profit margin | +5.3% | +5.5% | +0.7% | -6.2% | +6.8% | +14.0% | +15.4% |
| EPS (₹) | 25.22 | 53.13 | 4.88 | (3.84) | 26.00 | 52.51 | 56.39 |
| Balance sheet | |||||||
| Total assets | 13,048 | 10,762 | 9,748 | 9,431 | 8,612 | 7,692 | 10,572 |
| Net worth | 7,093 | 6,255 | 5,434 | 5,399 | 5,319 | 4,741 | 5,604 |
| Total debt | 3,615 | 2,731 | 3,664 | 3,677 | 3,192 | 2,830 | 4,808 |
| Cash & bank | 1,268 | 1,089 | 957 | 1,014 | 984 | 671 | 1,400 |
| Net working capital | 1,885 | 1,755 | 2,286 | 2,343 | 2,433 | 1,974 | 3,352 |
| Cash flow | |||||||
| Cash from operations | 1,227 | 1,072 | 971 | 661 | 838 | 1,784 | 1,543 |
| Cash from investing | (1,143) | 512 | (596) | (474) | (323) | (727) | (267) |
| Cash from financing | 94.90 | (1,453) | (432) | (157) | (32.60) | (1,709) | (1,050) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,370 | 2,229 | 2,290 | 2,122 | 1,966 | 1,901 | 1,929 | 1,822 |
| Revenue growth (YoY) | +20.5% | +17.3% | +18.7% | +16.5% | +12.2% | +9.8% | - | - |
| Other income | 14.40 | 19.90 | 23.70 | 20.50 | 9.80 | 12.00 | 11.90 | 9.20 |
| EBITDA | 240 | 248 | 326 | 250 | 336 | 290 | 342 | 268 |
| EBITDA margin | +10.2% | +11.2% | +14.3% | +11.8% | +17.1% | +15.4% | +17.9% | +14.8% |
| Depreciation | 135 | 127 | 117 | 121 | 105 | 98.10 | 95.20 | 91.30 |
| Interest | 58.40 | 54.20 | 56.50 | 56.10 | 50.20 | 49.00 | 52.70 | 55.60 |
| Profit before tax | 61.70 | 86.40 | 176 | 93.40 | 190 | 154 | 206 | 130 |
| Tax | 30.70 | 30.00 | 56.70 | 37.60 | 70.40 | 51.90 | 54.70 | 29.80 |
| Net profit | 31.00 | 56.40 | 119 | 55.80 | 120 | 102 | 151 | 101 |
| EPS (₹) | 1.97 | 3.56 | 7.52 | 3.52 | 7.57 | 6.47 | 9.68 | 6.36 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 264 | 231 | 785 | 810 | 726 | 2,710 | 3,140 |
| Revenue growth | +13.9% | -70.5% | -3.1% | +11.6% | -73.2% | -13.7% | - |
| EBITDA | 40.10 | 37.70 | 16.50 | 3.10 | 6.46 | 427 | 369 |
| EBITDA margin | +15.2% | +16.3% | +2.1% | +0.4% | +0.9% | +15.8% | +11.8% |
| Profit before tax | 72.50 | 38.40 | 41.70 | 79.30 | 84.72 | 273 | 299 |
| Net profit | 70.84 | 22.20 | 32.36 | 49.65 | 80.47 | 215 | 326 |
| Net profit margin | +26.9% | +9.6% | +4.1% | +6.1% | +11.1% | +7.9% | +10.4% |
| EPS (₹) | 3.97 | 1.21 | 1.99 | 3.14 | 5.05 | 13.46 | 20.16 |
| Balance sheet | |||||||
| Total assets | 2,377 | 2,682 | 2,782 | 2,784 | 2,646 | 1,791 | 4,687 |
| Net worth | 2,312 | 2,318 | 2,374 | 2,414 | 2,439 | 1,282 | 2,607 |
| Total debt | 52.70 | 336 | 380 | 346 | 183 | 504 | 2,013 |
| Cash & bank | 10.30 | 12.60 | 36.10 | 11.00 | 22.53 | 40.33 | 258 |
| Net working capital | (4.60) | 257 | 331 | 354 | 276 | 22.01 | 987 |
| Cash flow | |||||||
| Cash from operations | 93.60 | 136 | 143 | (65.10) | (3.55) | 608 | 317 |
| Cash from investing | 34.00 | (2.30) | (40.30) | 31.10 | 93.10 | 178 | (198) |
| Cash from financing | (130) | (157) | (77.80) | 22.50 | (107) | (782) | (41.05) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 68.50 | 67.10 | 70.30 | 67.30 | 66.40 | 59.50 | 60.70 | 56.10 |
| Revenue growth (YoY) | +3.2% | +12.8% | +15.8% | +20.0% | +8.1% | +11.8% | - | - |
| Other income | 0.90 | 0.10 | 0.50 | 0.40 | 42.40 | 2.40 | 13.00 | 2.80 |
| Total expenses | 56.80 | 55.10 | 64.50 | 55.10 | 54.60 | 49.20 | 49.80 | 46.10 |
| EBITDA | 11.70 | 12.00 | 5.80 | 12.20 | 11.80 | 10.30 | 10.90 | 10.00 |
| EBITDA margin | +17.1% | +17.9% | +8.3% | +18.1% | +17.8% | +17.3% | +18.0% | +17.8% |
| Depreciation | 1.30 | 1.40 | 1.30 | 1.60 | 1.60 | 1.50 | 1.50 | 1.50 |
| Interest | 1.00 | 0.90 | 0.90 | 0.90 | 2.50 | 3.00 | 3.10 | 3.30 |
| Profit before tax | 10.30 | 9.80 | 4.10 | 10.10 | 50.10 | 8.20 | 19.30 | 8.00 |
| Tax | 2.70 | 2.50 | (53.10) | 3.50 | 56.50 | 2.40 | 5.70 | 2.70 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,370 | 2,229 | 2,290 | 2,122 | 1,966 | 1,901 | 1,929 | 1,822 |
| Revenue growth (YoY) | +20.5% | +17.3% | +18.7% | +16.5% | +12.2% | +9.8% | - | - |
| Other income | 14.40 | 19.90 | 23.70 | 20.50 | 9.80 | 12.00 | 11.90 | 9.20 |
| EBITDA | 240 | 248 | 326 | 250 | 336 | 290 | 342 | 268 |
| EBITDA margin | +10.2% | +11.2% | +14.3% | +11.8% | +17.1% | +15.4% | +17.9% | +14.8% |
| Depreciation | 135 | 127 | 117 | 121 | 105 | 98.10 | 95.20 | 91.30 |
| Interest | 58.40 | 54.20 | 56.50 | 56.10 | 50.20 | 49.00 | 52.70 | 55.60 |
| Profit before tax | 61.70 | 86.40 | 176 | 93.40 | 190 | 154 | 206 | 130 |
| Tax | 30.70 | 30.00 | 56.70 | 37.60 | 70.40 | 51.90 | 54.70 | 29.80 |
| Net profit | 31.00 | 56.40 | 119 | 55.80 | 120 | 102 | 151 | 101 |
| EPS (₹) | 1.97 | 3.56 | 7.52 | 3.52 | 7.57 | 6.47 | 9.68 | 6.36 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 8,280 | 7,234 | 6,703 | 6,282 | 6,130 | 6,099 | 5,976 |
| Revenue growth | +14.5% | +7.9% | +6.7% | +2.5% | +0.5% | +2.1% | - |
| Other income | 66.00 | 416 | 92.80 | 50.60 | 11.29 | 291 | 258 |
| Total expenses | 7,079 | 6,061 | 5,971 | 5,562 | 4,984 | 4,723 | 4,461 |
| Employee cost | 2,701 | 2,268 | 2,216 | 2,166 | 2,043 | 1,923 | 1,843 |
| EBITDA | 1,200 | 1,173 | 732 | 719 | 1,146 | 1,375 | 1,515 |
| EBITDA margin | +14.5% | +16.2% | +10.9% | +11.5% | +18.7% | +22.6% | +25.4% |
| Depreciation | 440 | 369 | 382 | 554 | 382 | 349 | 340 |
| Interest | 212 | 240 | 272 | 188 | 145 | 184 | 200 |
| Profit before tax | 614 | 981 | 170 | 27.80 | 630 | 1,133 | 1,233 |
| Tax | 217 | 144 | 97.80 | 92.70 | 217 | 297 | 335 |
| Net profit | 436 | 400 | 45.30 | (389) | 416 | 856 | 922 |
| Net profit margin | +5.3% | +5.5% | +0.7% | -6.2% | +6.8% | +14.0% | +15.4% |
| EPS (₹) | 25.22 | 53.13 | 4.88 | (3.84) | 26.00 | 52.51 | 56.39 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 15.80 | 15.80 | 15.80 | 15.90 | 15.92 | 15.92 | 15.93 |
| Reserves & surplus | 7,077 | 6,239 | 5,418 | 5,383 | 5,303 | 4,726 | 5,588 |
| Shareholders' funds (net worth) | 7,093 | 6,255 | 5,434 | 5,399 | 5,319 | 4,741 | 5,604 |
| Minority interest | 2.80 | (16.30) | (12.80) | (7.50) | (2.16) | 0.03 | 0.00 |
| Secured loans | 540 | 456 | 496 | 523 | 265 | 40.78 | 999 |
| Unsecured loans | 3,074 | 2,275 | 3,168 | 3,153 | 2,927 | 2,789 | 3,810 |
| Total debt | 3,615 | 2,731 | 3,664 | 3,677 | 3,192 | 2,830 | 4,808 |
| Total liabilities | 13,048 | 10,762 | 9,748 | 9,431 | 8,612 | 7,692 | 10,572 |
| Assets | |||||||
| Gross block | 10,167 | 7,823 | 7,869 | 7,368 | 6,692 | 6,090 | 7,983 |
| Net block | 6,966 | 5,176 | 5,091 | 5,183 | 4,871 | 4,609 | 6,340 |
| Capital work in progress | 4,040 | 3,630 | 2,103 | 1,562 | 1,090 | 897 | 768 |
| Investments | 61.40 | 43.50 | 42.20 | 256 | 239 | 241 | 69.36 |
| Inventories | 1,232 | 1,129 | 1,290 | 1,380 | 1,255 | 1,129 | 1,845 |
| Sundry debtors | 1,070 | 892 | 916 | 961 | 928 | 820 | 1,293 |
| Cash & bank balances | 1,268 | 1,089 | 957 | 1,014 | 984 | 671 | 1,400 |
| Loans & advances | 541 | 468 | 714 | 406 | 342 | 332 | 500 |
| Total current assets | 4,109 | 3,577 | 3,876 | 3,762 | 3,509 | 2,952 | 5,038 |
| Total current liabilities | 2,224 | 1,822 | 1,590 | 1,419 | 1,076 | 979 | 1,686 |
| Net working capital | 1,885 | 1,755 | 2,286 | 2,343 | 2,433 | 1,974 | 3,352 |
| Total assets | 13,048 | 10,762 | 9,748 | 9,431 | 8,612 | 7,692 | 10,572 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 1,088 | 956 | 1,014 | 984 | 502 | 1,154 | 1,005 |
| Net cash from operating activities | 1,227 | 1,072 | 971 | 661 | 838 | 1,784 | 1,543 |
| Net cash from investing activities | (1,143) | 512 | (596) | (474) | (323) | (727) | (267) |
| Net cash from financing activities | 94.90 | (1,453) | (432) | (157) | (32.60) | (1,709) | (1,050) |
| Net change in cash | 179 | 132 | (57.50) | 30.10 | 482 | (652) | 225 |
| Closing cash | 1,268 | 1,089 | 957 | 1,014 | 984 | 671 | 1,400 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +14.5% | +7.9% | +6.7% | +2.5% | +0.5% | +2.1% | - |
| EBITDA growth | +2.3% | +60.3% | +1.7% | -37.2% | -16.6% | -9.2% | - |
| PBT growth | -37.4% | +475.1% | +513.3% | -95.6% | -44.4% | -8.2% | +36.5% |
| Net income growth | +9.1% | +782.1% | +111.6% | -193.5% | -51.4% | -7.1% | - |
| Revenue CAGR (3Y) | +9.6% | +5.7% | +3.2% | +1.7% | -12.4% | -6.7% | +0.7% |
| EBITDA CAGR (3Y) | +18.6% | +0.8% | -19.0% | -22.0% | -7.7% | -3.3% | +4.0% |
| Profitability & leverage | |||||||
| Net income margin | +4.8% | +11.6% | +1.1% | -1.0% | +6.7% | +13.7% | +15.0% |
| Return on capital employed | +6.9% | +8.4% | +6.4% | +3.1% | +9.5% | +11.9% | +14.1% |
| Return on net worth | +6.0% | +6.8% | +0.8% | -7.3% | +8.2% | +16.6% | +17.3% |
| Debt / equity | 0.48 | 0.55 | 0.68 | 0.64 | 0.60 | 0.74 | 0.93 |
| Long-term debt / equity | 0.43 | 0.49 | 0.62 | 0.56 | 0.54 | 0.64 | 0.78 |
| Interest cover | 27.87 | 29.87 | 77.80 | 113.78 | 19.03 | 17.94 | 16.99 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.92 | 0.92 | 0.88 | 0.89 | 0.96 | 0.87 | 0.80 |
| Inventory turnover | 7.01 | 5.98 | 5.02 | 4.77 | 5.14 | 4.10 | 3.66 |
| Debtors turnover | 8.44 | 8.01 | 7.14 | 6.65 | 7.01 | 5.77 | 4.66 |
| EPS (₹) | 25.22 | 53.13 | 4.88 | (3.84) | 26.00 | 52.51 | 56.39 |
| Dividend per share (₹) | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Book value per share (₹) | 448.91 | 395.88 | 343.92 | 339.58 | 334.10 | 297.85 | 351.78 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 68.50 | 67.10 | 70.30 | 67.30 | 66.40 | 59.50 | 60.70 | 56.10 |
| Revenue growth (YoY) | +3.2% | +12.8% | +15.8% | +20.0% | +8.1% | +11.8% | - | - |
| Other income | 0.90 | 0.10 | 0.50 | 0.40 | 42.40 | 2.40 | 13.00 | 2.80 |
| Total expenses | 56.80 | 55.10 | 64.50 | 55.10 | 54.60 | 49.20 | 49.80 | 46.10 |
| EBITDA | 11.70 | 12.00 | 5.80 | 12.20 | 11.80 | 10.30 | 10.90 | 10.00 |
| EBITDA margin | +17.1% | +17.9% | +8.3% | +18.1% | +17.8% | +17.3% | +18.0% | +17.8% |
| Depreciation | 1.30 | 1.40 | 1.30 | 1.60 | 1.60 | 1.50 | 1.50 | 1.50 |
| Interest | 1.00 | 0.90 | 0.90 | 0.90 | 2.50 | 3.00 | 3.10 | 3.30 |
| Profit before tax | 10.30 | 9.80 | 4.10 | 10.10 | 50.10 | 8.20 | 19.30 | 8.00 |
| Tax | 2.70 | 2.50 | (53.10) | 3.50 | 56.50 | 2.40 | 5.70 | 2.70 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 264 | 231 | 785 | 810 | 726 | 2,710 | 3,140 |
| Revenue growth | +13.9% | -70.5% | -3.1% | +11.6% | -73.2% | -13.7% | - |
| Other income | 45.70 | 20.20 | 103 | 138 | 126 | 47.88 | 173 |
| Total expenses | 223 | 194 | 768 | 807 | 719 | 2,282 | 2,771 |
| Employee cost | 104 | 92.10 | 190 | 167 | 164 | 221 | 265 |
| EBITDA | 40.10 | 37.70 | 16.50 | 3.10 | 6.46 | 427 | 369 |
| EBITDA margin | +15.2% | +16.3% | +2.1% | +0.4% | +0.9% | +15.8% | +11.8% |
| Depreciation | 6.00 | 6.60 | 48.30 | 43.20 | 36.91 | 99.97 | 107 |
| Interest | 7.30 | 12.90 | 29.90 | 18.50 | 10.99 | 102 | 136 |
| Profit before tax | 72.50 | 38.40 | 41.70 | 79.30 | 84.72 | 273 | 299 |
| Tax | 9.30 | 19.20 | 10.10 | 29.40 | 4.23 | 58.69 | (22.30) |
| Net profit | 70.84 | 22.20 | 32.36 | 49.65 | 80.47 | 215 | 326 |
| Net profit margin | +26.9% | +9.6% | +4.1% | +6.1% | +11.1% | +7.9% | +10.4% |
| EPS (₹) | 3.97 | 1.21 | 1.99 | 3.14 | 5.05 | 13.46 | 20.16 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 15.90 | 15.90 | 15.90 | 15.90 | 15.93 | 15.93 | 15.93 |
| Reserves & surplus | 2,296 | 2,302 | 2,359 | 2,399 | 2,423 | 1,267 | 2,591 |
| Shareholders' funds (net worth) | 2,312 | 2,318 | 2,374 | 2,414 | 2,439 | 1,282 | 2,607 |
| Secured loans | 50.00 | 213 | 261 | 222 | 95.00 | 95.00 | 899 |
| Unsecured loans | 2.70 | 123 | 119 | 123 | 87.52 | 409 | 1,114 |
| Total debt | 52.70 | 336 | 380 | 346 | 183 | 504 | 2,013 |
| Total liabilities | 2,377 | 2,682 | 2,782 | 2,784 | 2,646 | 1,791 | 4,687 |
| Assets | |||||||
| Gross block | 156 | 1,036 | 997 | 947 | 863 | 149 | 2,288 |
| Net block | 116 | 699 | 711 | 687 | 637 | 127 | 1,865 |
| Capital work in progress | 11.50 | 19.30 | 37.00 | 47.00 | 35.26 | 0.33 | 59.09 |
| Investments | 2,176 | 1,657 | 1,657 | 1,657 | 1,646 | 1,646 | 1,764 |
| Inventories | 0.00 | 232 | 251 | 314 | 323 | 0.00 | 656 |
| Sundry debtors | 23.80 | 206 | 194 | 188 | 131 | 0.00 | 425 |
| Cash & bank balances | 10.30 | 12.60 | 36.10 | 11.00 | 22.53 | 40.33 | 258 |
| Loans & advances | 16.80 | 32.90 | 59.40 | 65.70 | 49.40 | 25.92 | 383 |
| Total current assets | 50.90 | 484 | 541 | 579 | 526 | 66.25 | 1,722 |
| Total current liabilities | 55.50 | 227 | 210 | 225 | 250 | 44.24 | 735 |
| Net working capital | (4.60) | 257 | 331 | 354 | 276 | 22.01 | 987 |
| Total assets | 2,377 | 2,682 | 2,782 | 2,784 | 2,646 | 1,791 | 4,687 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 12.60 | 36.10 | 11.00 | 22.50 | 40.35 | 35.64 | 18.70 |
| Net cash from operating activities | 93.60 | 136 | 143 | (65.10) | (3.55) | 608 | 317 |
| Net cash from investing activities | 34.00 | (2.30) | (40.30) | 31.10 | 93.10 | 178 | (198) |
| Net cash from financing activities | (130) | (157) | (77.80) | 22.50 | (107) | (782) | (41.05) |
| Net change in cash | (2.30) | (23.50) | 25.10 | (11.50) | (17.82) | 4.69 | 78.00 |
| Closing cash | 10.30 | 12.60 | 36.10 | 11.00 | 22.53 | 40.33 | 258 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +13.9% | -70.5% | -3.1% | +11.6% | -73.2% | -13.7% | - |
| EBITDA growth | +6.4% | +128.5% | +432.3% | -52.0% | -98.5% | +15.7% | - |
| PBT growth | +88.8% | -7.9% | -47.4% | -6.4% | -69.0% | -8.6% | +62.9% |
| Net income growth | +219.1% | -31.4% | -34.8% | -38.3% | -62.5% | -34.2% | - |
| Revenue CAGR (3Y) | -31.2% | -31.7% | -33.8% | -36.3% | -40.5% | -6.4% | +8.0% |
| EBITDA CAGR (3Y) | +134.7% | +80.0% | -66.2% | -79.7% | -72.8% | -7.5% | +5.1% |
| Profitability & leverage | |||||||
| Net income margin | +24.0% | +8.3% | +4.0% | +6.2% | +11.1% | +7.9% | +10.2% |
| Return on capital employed | +1.8% | +1.9% | +2.6% | +3.6% | +4.3% | +11.6% | +9.9% |
| Return on net worth | +3.1% | +0.8% | +1.3% | +2.1% | +4.3% | +11.0% | +13.0% |
| Debt / equity | 0.08 | 0.15 | 0.15 | 0.11 | 0.18 | 0.65 | 0.75 |
| Long-term debt / equity | 0.05 | 0.10 | 0.10 | 0.08 | 0.16 | 0.46 | 0.44 |
| Interest cover | 21.41 | 41.48 | -94.03 | -46.13 | -36.09 | 31.12 | 52.02 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.44 | 0.23 | 0.81 | 0.89 | 1.43 | 2.22 | 1.53 |
| Inventory turnover | 2.27 | 0.96 | 2.78 | 2.54 | 4.49 | 8.26 | 5.47 |
| Debtors turnover | 2.29 | 1.16 | 4.10 | 5.08 | 11.11 | 12.74 | 6.93 |
| EPS (₹) | 3.97 | 1.21 | 1.99 | 3.14 | 5.05 | 13.46 | 20.16 |
| Dividend per share (₹) | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Book value per share (₹) | 145.43 | 145.79 | 149.34 | 151.86 | 153.11 | 80.51 | 163.67 |
Similar companies to Jubilant Pharmova
Jubilant Pharmova has 3 listed similar companies in our database, 2 of them funded. They include Akums, Jubilant Life Sciences and Nectar Lifesciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| akums.in | 2004 | Delhi, India | $70M | 395 | CDMO focusing on spectrum of dosage forms and therapeutic segments | |
| jubl.com | 1978 | Noida, India | Company offering a suite of R&D and manufacturing services for small molecules and generics | |||
| neclife.com | 1995 | Chandigarh, India | $46.85M | 175 | Cephalosporin APIs and generic formulations are manufactured. |
Detailed similar companies of Jubilant Pharmova
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Jubilant Pharmova
The website of Jubilant Pharmova (jubilantpharmova.com) receives about 7K visits a month.
- Monthly visits7K
▼ 16% vs previous month
Websites whose visitors overlap most with Jubilant Pharmova. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| granulesindia.com | 100% | 14.1K | #1,691,049 | View details | |
| rakesh-jhunjhunwala.in | 94% | #1,251,634 | View details | ||
| jubl.com | 71% | 48.5K | #611,852 | View details | |
| jubilantpharma.com | 24% | 7K | View details | ||
| jubilantindustries.com | 24% | 1.9K | #8,593,046 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Jubilant Pharmova
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Jubilant Pharmova (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Jubilant Pharmova
Complete news archive for Jubilant Pharmova
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jubilant Pharmova
Jubilant Pharmova was founded in 2020.
Jubilant Pharmova is headquartered in Amroha, India. It is registered at Amroha, Uttar Pradesh, India.
Jaidev Rajpal is the CEO of Jubilant Pharmova, as recorded in our data.
Jubilant Pharmova has 165 employees.
The primary company behind Jubilant Pharmova, Jubilant Pharmova Limited, reported revenue of ₹8,346 Cr for FY 2026, up 14% year on year.
Jubilant Pharmova was founded in 2020 in Amroha, India, within the pharmaceutical sector. Operations are centered on contract development and manufacturing services for solid, semi-solid, liquid, and injectable drug formulations. The company is headquartered in India, with its domain registered as jubilantpharmova.com. Leadership is provided by CEO Jaidev Rajpal, overseeing production activities for pharmaceutical clients.
Jubilant Pharmova's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
Yes, Jubilant Pharmova is publicly traded on NSE under the ticker symbol JUBLPHARMA.
Jubilant Pharmova is associated with 2 legal entities: Jubilant Pharmova Limited, Vanthys Pharmaceutical Development Private Limited.
The legal entities of Jubilant Pharmova currently have 17 directors, including Nitin Garg, Benny Thomas, Saravanakumar Dhakshinamoorthy and others.

